WESTMINSTER, Colo.--(BUSINESS WIRE)--Oct. 7, 2009--
Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced the pricing of an
underwritten public offering of 14,000,000 primary shares of its common
stock at a public offering price of $7.10 per share. The gross proceeds
from the sale of the shares, before underwriting discounts and
commissions and other offering expenses, are expected to be
approximately $99.4 million. The offering is expected to close on or
about October 13, 2009, subject to customary closing conditions. Allos
has also granted the underwriters a 30-day option to purchase up to an
aggregate of 2,100,000 additional shares of common stock to cover
over-allotments, if any. All of the shares in the offering are being
sold by Allos.
Allos currently anticipates using the net proceeds of the offering
primarily for activities relating to the commercialization of FOLOTYN™
(pralatrexate injection), preclinical research and clinical development
of FOLOTYN, and for general corporate purposes.
J.P. Morgan Securities Inc. and Citigroup Global Markets Inc. are acting
as joint book-running managers of the offering. Leerink Swann LLC is
acting as co-lead manager of the offering. JMP Securities LLC, Needham &
Company, LLC, and RBC Capital Markets are acting as co-managers of the
offering. A copy of the final prospectus supplement and accompanying
prospectus relating to the offering, when available, may be obtained by
contacting J.P. Morgan Securities Inc., Attention: Prospectus
Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by
calling (718) 242-8002 or Citigroup Global Markets Inc., Prospectus
Department, Brooklyn Army Terminal, 140 58th Street, 8th Floor,
Brooklyn, NY 11220, (800) 831-9146.
A registration statement relating to these shares was declared effective
by the Securities and Exchange Commission on August 28, 2009. Any offer
or sale will be made only by means of a written prospectus supplement
forming part of the effective registration statement. This press release
does not and shall not constitute an offer to sell or the solicitation
of an offer to buy Allos’ common stock, nor shall there be any sale of
the common stock in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any state.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq:ALTH) is a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics.
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements include
statements concerning the Company’s expectations regarding completion,
timing and size of the proposed financing and other statements which are
other than statements of historical facts. In some cases, you can
identify forward-looking statements by terminology such as "may,"
"will," "should," "expects," "intends," "plans," anticipates,"
"believes," "estimates," "predicts," "projects," "potential,"
"continue," and other similar terminology or the negative of these
terms, but their absence does not mean that a particular statement is
not forward-looking. Such forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties that
may cause actual results to differ materially from those anticipated by
the forward-looking statements. These risks and uncertainties include,
among others: the risk that the financing may be delayed or may not
occur due to market or other conditions and the satisfaction of
customary closing conditions related to the proposed public offering.
Additional information concerning these and other factors that may cause
actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Quarterly Report on Form 10-Q for the quarter ended June
30, 2009, and in the Company's other periodic reports and filings with
the Securities and Exchange Commission and the prospectus supplement
related to the offering. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of this
presentation, except as required by law.
Note: Allos Therapeutics, Inc., the Allos Therapeutics, Inc. logo,
FOLOTYN, the FOLOTYN logo and all other Allos names are trademarks of
Allos Therapeutics, Inc. in the United States and in other selected
countries.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
mgreer@allos.com
